Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

Viral immunologist Paul Thomas, PhD, is working to turn the “incredible potential” of the immune system into real-life diagnostic and therapeutic applications that will improve vaccination strategies ...

Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...

Affiliate Professor, Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch Affiliate Professor, Herbold Computational Biology Program Public Health Sciences Division, Fred ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...

When Don Stranathan’s left leg became swollen after a long day of shoveling granite for a buddy’s new bocce ball court, he didn’t think much of it. He even joked about it on Facebook. “Typical me, I ...

Bisphosphonates are popular bone-targeting drugs. Older people take them to prevent and treat osteoporosis. Breast cancer patients, particularly those with metastatic disease, take them to prevent and ...